Theranostics is a novel treatment strategy based on the use of targeted drug therapy in the detection and management of disease. The theranostic tests differ from standard blood glucose tests by using sophisticated technology, including molecular biology and genetics. Theranostic tests are based on microchips and testing platforms. They also target specific genes in the body to provide specific treatment. By combining a targeted therapy and a diagnostic test, theranostics offers a new level of care for patients and improved outcomes.
Ultimately, the goal of theranostics is to improve patient care by targeting the most effective drugs for specific patients. By using new diagnostics, doctors can determine which patients will benefit from a particular drug. This process can be extremely helpful in expediting diagnosis and saving patients’ money on ineffective treatments. Further, theranostics can help diagnose cancer sooner, without waiting for a lab’s results. As a result, theranostics has transformed health care.
Imaging is central to patient care and has been instrumental in the discovery of drugs. Theranostics allows physicians to more accurately predict the response of a drug to a given treatment, tissue toxicity, and prognosis. Moreover, it combines diagnostics and therapy, making them an effective tool for patient care.
According to Coherent Market Insights, development of novel companion diagnostic tests to be used with available treatment options is expected to boost the global theranostics market growth over the forecast period. Leading manufacturers are engaged in introduction of novel companion diagnostic tests in market. For instance, Illumina, Inc. announced launch of the U.S. Food & Drug Administration (FDA) approved extended RAS panel for identification of patients eligible for treatment of metastatic colorectal cancer with Vectibix (panitumumab) in 2017.
Theranostics was first proposed in 2002 and has been applied since then. It is a growing field in medicine and is a valuable resource for personalized care. Currently, conventional cancer treatments lack specificity and are associated with high systemic toxicity. Theranostics, on the other hand, focuses on patient-centered care. Its goal is to provide an ideal transition from conventional medicine to personalized medicine. Its focus on genetics, proteomics, and biomarker profiling are the core pillars of the theranostics process. As a new technology for cancer diagnosis, theranostics is transforming the field of medicine. This new technology is also becoming an invaluable tool for individualized pharmacotherapy. It is a growing field of medicine involving the integration of diagnostics and therapeutics. In June 2021, GE Healthcare revealed new precision health and theranostics molecular imaging products and solutions at 2021 summer conference of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in the U.S.